^
9d
Genetics in medicine publishes Myriad Genetics patient-outcomes study validating RiskScore® as a clinical breast cancer risk assessment tool (Myriad Genetics Press Release)
" Myriad Genetics, Inc...announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator."
Clinical data
|
Myriad myRisk® Hereditary Cancer
13d
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications (Myriad Genetics Press Release)
"QIAGEN...and Myriad Genetics...announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies."
Licensing / partnership
|
Myriad myChoice® CDx
20d
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and collaborators (Myriad Genetics Press Release)
"Myriad Genetics...and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR)."
Licensing / partnership
|
Myriad myChoice® CDx • Precise™ MRD
27d
New study published in JCO Precision Oncology shows Myriad Genetics’ Prolaris test can predict benefit of hormone therapy treatment in men with localized prostate cancer (Myriad Genetics Press Release)
"Myriad Genetics...announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer."
Clinical data
|
Prolaris®
28d
UK's NICE expands tumor profiling recommendations for guiding adjuvant chemo in early breast cancer (Genomeweb)
"The UK National Institute for Health and Care Excellence (NICE)...recommended three prognostic gene expression tests as tools for guiding adjuvant chemotherapy treatment decisions in an expanded population of early breast cancer patients...In a final guidance, NICE said Myriad Genetics' EndoPredict (which is being sold to Eurobio), Veracyte's Prosigna, and Exact Sciences' Oncotype DX can be used within the National Health Service (NHS) to guide adjuvant treatment for postmenopausal women or men with estrogen receptor-positive, HER2-negative early breast cancer and one to three positive lymph nodes."
NICE
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
1m
Myriad Genetics announces reorganization of European operations and Sale of EndoPredict business (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States."
Licensing / partnership
|
EndoPredict® • Prolaris®
2ms
INTERACT coalition formed to advance patient access to genetic testing for hereditary cancer risk (PRNewswire)
"Leading commercial organizations and patient advocacy groups in the field of cancer genetics...announced the founding of the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT), a coalition whose mission is to increase evidence-based access to genetic testing for people with or at risk of hereditary cancers...The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk."
Licensing / partnership
3ms
Myriad Genetics announces foundational patent granted for Molecular Residual Disease (MRD) with early priority date (Myriad Genetics Press Release)
"Myriad Genetics...announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market."
Patent
|
Precise™ MRD
4ms
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 (GlobeNewswire)
"Myriad Genetics, Inc...today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) over time in patients diagnosed with a wide array of solid tumor and hematological cancers...The SCRUM-MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino of the NCCHE, will explore how multi-omic profiling can be used to develop more personalized treatment and therapeutic strategies in three study cohorts."
Licensing / partnership • Minimal residual disease
|
Precise™ MRD
4ms
Myriad Genetics completes acquisition of Precise Tumor, Precise Liquid and laboratory from Intermountain Precision Genomics (Myriad Genetics Press Release)
"Myriad Genetics...announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah."
M&A
|
Precise™ Liquid • Precise™ Tumor Molecular Profile Test
5ms
Myriad Genetics to acquire Precise Tumor, Precise Liquid and laboratory from Intermountain Precision Genomics (Myriad Genetics Press Release)
"Myriad Genetics...announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed."
M&A
|
Precise™ Liquid • Precise™ Tumor Molecular Profile Test
5ms
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO (GlobeNewswire)
"Myriad Genetics...announced its support for the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer. The new guideline offers multi-pronged, evidence-based clinical practice recommendations. Among the guidance includes: (i) All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing; (ii) All patients with a current or previous diagnosis of invasive breast cancer > 65 years should be offered BRCA1/2 testing if personal or family history suggests the possibility of a pathogenic variant or are candidates for a PARP inhibitor therapy."
Clinical guideline
6ms
Myriad Genetics establishes comprehensive pan-cancer research platform to advance patient care (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the launch of the Myriad Collaborative Research Registry (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients."
Clinical
7ms
Myriad Genetics and Personalis partner to market solutions to pharma customers (Personalis Press Release)
"Myriad Genetics, Inc...and Personalis, Inc...announced a non-exclusive collaboration through which Myriad will market the Personalis®ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests."
Licensing / partnership
|
BRACAnalysis CDx™ • Myriad myChoice® CDx • Myriad myRisk® Hereditary Cancer
8ms
Qiagen and Myriad Genetics partner to advance companion diagnostics development for cancer (Myriad Genetics Press Release)
"QIAGEN...and Myriad Genetics...announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer...The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market, and providing distributable companion diagnostic test kits for the global market."
Licensing / partnership
9ms
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials (GlobeNewswire)
"Myriad Genetics, Inc...today announced two key milestones in its strategic partnership with Illumina Inc...to advance and support clinical research for gene-based, targeted therapies....Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency (HRD) testing using the globally distributed Illumina TruSight Oncology 500 (TSO 500) assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants."
Licensing / partnership
|
TruSight Oncology 500 Assay
9ms
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer (GlobeNewswire)
"Myriad Genetics, Inc...announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer. The research project will use Myriad’s MRD testing platform, a tumor-informed high-definition assay that uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA (ctDNA)."
Licensing / partnership
10ms
Myriad Genetics and Onsite Women’s Health partner to help more women understand breast cancer risk (Myriad Genetics Press Release)
"Myriad Genetics, Inc...and Onsite Women’s Health, a leading national provider of breast health services...announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk."
Licensing / partnership
|
Myriad myRisk® Hereditary Cancer
10ms
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris (GlobeNewswire)
"Myriad Genetics, Inc...announced the integration of Absolute Risk Reduction (ARR) into the Prolaris® Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy. Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT)."
Clinical
|
Prolaris®
10ms
Myriad Genetics and Intermountain Health participate in ComboMATCH, a national clinical trial to advance cancer treatment (Myriad Genetics Press Release)
"Myriad Genetics, Inc...and Intermountain Precision Genomics, part of the Intermountain Health system, will begin providing oncology test results that allow access to the ComboMATCH trials. ComboMATCH is a coordinated platform of clinical oncology trials sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health."
Clinical
11ms
Myriad Genetics Announces Inclusion of Breast Density to MyRisk with RiskScore Breast Cancer Risk Assessment (GlobeNewswire)
"Myriad Genetics, Inc...announced its MyRisk® Hereditary Cancer Test with RiskScore® now incorporates breast density using Tyrer-Cuzick version 8 (TCv8) to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer....The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024."
Clinical
|
Myriad myRisk® Hereditary Cancer
1year
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform (GlobeNewswire)
"Myriad Genetics, Inc...announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response. The project will use Myriad’s minimal residual disease (MRD) testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA (ctDNA)....The research team will investigate the use of Myriad’s MRD testing platform as a non-invasive tool to inform treatment selection, surveillance, and radiotherapy treatment response in individuals with metastatic renal cell carcinoma (RCC)....The goal of this research is to determine if patients with RCC will benefit from a comprehensive genome-wide approach to MRD with this platform."
Licensing / partnership
1year
Myriad Genetics adds folate receptor alpha to precise oncology solutions portfolio to expand treatment options for women living with ovarian cancer (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the addition of Folate Receptor Alpha (FRα) to its Precise Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer."
Clinical
1year
Myriad Genetics and Intermountain Precision Genomics now offer solid tumor testing in all 50 states with latest NY state certification (Myriad Genetics Press Release)
"Myriad Genetics, Inc...and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit."
Regulatory
|
Precise™ Tumor Molecular Profile Test • TheraMap Test
1year
Myriad Genetics and SimonMed Imaging collaborate to advance precision medicine with new genetic risk assessment program (Myriad Genetics Press Release)
"Myriad Genetics, Inc...and SimonMed Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education."
Licensing / partnership
|
Myriad myRisk® Hereditary Cancer
over1year
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States (Illumina Press Release)
"Illumina...and Myriad Genetics...announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) testing in the United States. Under the agreement, Illumina TruSight™ Oncology 500 HRD (TSO 500 HRD), a research-use-only test, is now available in the US. The expanded partnership also establishes a unique companion diagnostic (CDx) alliance for the pharmaceutical industry, which will enable more clinical research for gene-based, targeted therapies."
Licensing / partnership
|
TruSight Oncology 500 HRD Assay
over1year
Myriad Genetics patient outcomes study shows RiskScore leads to more accurate breast cancer risk prediction than standard-of-care risk model (Myriad Genetics Press Release)
"Myriad Genetics, Inc...presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium."
Clinical data
|
Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment (Myriad Genetics Press Release)
"Myriad Genetics...announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction....Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies....Additionally, there will also be poster session (P6-01-24) about an independent EndoPredict study....The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer."
Clinical data
|
BRACAnalysis CDx™ • Myriad myChoice® CDx • EndoPredict® • Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting (Myriad Genetics Press Release)
"Myriad Genetics, Inc...will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn...My Risk with Risk Score, Myriad’s market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries. RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk. JCO Precision Oncology recently published a study1 that highlights the development and validation of RiskScore for women of all ancestries. The study examined data from more than 275,000 women of diverse ancestral backgrounds to validate the use of ancestry-informative genetic markers. Results showed the new method was more accurate for women of all ancestries."
Clinical data • Clinical
|
Myriad myRisk® Hereditary Cancer
over1year
Myriad Genetics Announces UroSuite, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care....UroSuite includes Myriad’s Prolaris® Prostate Cancer Test, MyRisk™ Hereditary Cancer Test, BRACAnalysis CDx® and Precise™ Tumor Molecular Profile Test. The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients....'Today’s launch of UroSuite reinforces Myriad Genetics’ commitment to advancing health and well-being for all through a set of testing solutions for prostate cancer care, best-in-class support, and access to genetics and cancer specialists,' said Paul J. Diaz, president and CEO, Myriad Genetics."
Launch • Clinical
|
BRACAnalysis CDx™ • Myriad myRisk® Hereditary Cancer • Precise™ Tumor Molecular Profile Test • Prolaris®
almost2years
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients (Myriad Genetics Press Release)
P=Obs | N=855 | NCT04016935 | "Myriad Genetics, Inc...announced today Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study 1 that shows the EndoPredict® breast cancer prognostic test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer....The study shows that patients with EndoPredict low-risk scores had a 97% distant recurrence free survival (DRFS) versus 76% for high-risk patients. Importantly, 19% of node-positive premenopausal patients had EndoPredict low-risk scores with 100% DRFS and were able to safely avoid chemotherapy and continue onto endocrine therapy alone....Another key result from an exploratory subgroup analysis within the study found similar DRFS rates in low-risk patients with or without ovarian function suppression (OFS), with less than 5% distant recurrence after 10 years in both groups."
Clinical data • Observational data
|
EndoPredict®
almost2years
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis Diagnostic System as a Companion Diagnostic for Lynparza in Early-Stage Breast Cancer (Myriad Genetics Press Release)
"Myriad Genetics...announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted expanded coverage for the use of Myriad’s BRACAnalysis Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza (olaparib)."
Japanese regulatory
|
BRACAnalysis CDx™
|
Lynparza (olaparib)
almost2years
Myriad Genetics, Clarified Precision Medicine team up on molecular tumor board service (Precision Medicine Online)
"Clarified Precision Medicine said Wednesday that it is partnering with Myriad Genetics to make it easier for oncologists using Myriad's suite of cancer genetic tests to access expert interpretation of results through a newly formed molecular tumor board."
Licensing / partnership
almost2years
Myriad Genetics partners with Institut fur Hämopathologie Hamburg and Centre Georges-Francois LeClerc to expand access to genetic testing in Europe (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced two partnerships with the Institut für Hämopathologie Hamburg (HPH) in Hamburg, Germany and the Centre Georges-Francois LeClerc (CGFL) in Dijon, France to expand access to MyChoice® CDx Plus testing. HPH and CGFL join Myriad’s network of partner laboratories to help support equitable patient access to genetic testing in key European markets."
Licensing / partnership
|
Myriad myChoice® CDx
almost2years
Myriad Genetics teams up with Epic to make genetic testing accessible to more patients with Electronic Health Record (EHR) integration (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad’s full line of genetic tests with Epic’s expansive network of 600,000 physicians and more than 250 million patients."
Licensing / partnership
2years
Myriad Genetics showcases advancements in precision medicine with recent oncology portfolio expansion and new data presentations at ASCO 2022 (Myriad Genetics Press Release)
"Myriad Genetics, Inc...will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment...The presentations underscore Myriad’s commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-driven insights to help guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profiling, and companion diagnostic options, including evaluation for homologous recombination deficiency (HRD)."
Clinical data
2years
Myriad Genetics expands partnership with Intermountain Precision Genomics to add liquid biopsy therapy selection offering to portfolio of Precise™ oncology solutions (Myriad Genetics Press Release)
Myriad Genetics, Inc...announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio...The collaboration and platform established for Myriad’s recently launched Precise™ Tumor Molecular Profile Test leverages the strengths of Myriad’s hereditary cancer and companion diagnostic tests with Intermountain’s world-class laboratory services."
Licensing / partnership
|
Precise™ Tumor Molecular Profile Test
2years
Myriad Genetics advances precision oncology with new Precise™ Solutions, combines genetic insights from multiple tests to guide treatment decisions and improve patient care (Myriad Genetics Press Release)
"Myriad Genetics, Inc...announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients. The new suite provides physicians with streamlined testing that combines germline testing, tumor profiling and companion diagnostic options including evaluation for Homologous Recombination Deficiency (HRD), an important cancer repair pathway...Precise Oncology Solutions includes Myriad’s new Precise™ Tumor Molecular Profile Test, developed in collaboration with Intermountain Precision Genomics, leading healthcare providers, and industry partners."
Launch
|
Precise™ Tumor Molecular Profile Test
over2years
Myriad Genetics Receives FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Lynparza in Early Breast Cancer (Myriad Genetics Press Release)
"Myriad Genetics...announced the U.S. Food and Drug Administration (FDA) has approved Myriad’s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza (olaparib)....BRACAnalysis CDx is intended to detect and interpret germline BRCA1 and BRCA2 variants. The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2 negative high-risk early breast cancer."
FDA event
|
BRACAnalysis CDx™
|
Lynparza (olaparib)
over2years
Myriad Genetics to present new data at San Antonio Breast Cancer Symposium highlighting value of genetic testing in breast cancer risk assessment and treatment (Myriad Genetics Press Release)
"Myriad Genetics, Inc...two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment."
Clinical